Search
David Shapiro, Chair of Saul Ewing's Tax and Employee Benefits Practice, will moderate a panel at the ABA Section of Taxation 2023 May Tax Meeting on May 5, 2023. The session is entitled "Current Developments in Inbound International Tax and Treaties." The panel will discuss recent and anticipated...
On April 5, 2023, Saul Ewing Partner Andy Daly spoke to the Arrowhead Estate Planning Counsel in Duluth, MN on ESOPs and Estate Planning .
David Shapiro will be speaking on February 10, 2023 during the ABA 2023 Midyear Tax Meeting being held February 9, 2023 – February 11, 2023 at the Hilton San Diego Bayfront. David is part of the Cryptocurrency Task Force and will be on a panel that will be speaking on "Shining a Light on Digital...
Saul Ewing attorneys hosted this fast-paced webinar, providing a list of things you need to know to develop your checklist for legal issues in 2023, from employment, corporate governance, cybersecurity and privacy, intellectual property to tax. Attorneys with specialized knowledge in these areas...
Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...
TAX TREATY PRIMER—AN OVERVIEW OF TAX TREATIES AND TAX TREATY PLANNING TECHNIQUES David Shapiro, Chair of the Firm's Tax Practice, will be speaking at the NYU School of Professional Studies on Monday, July 11, 2022. His topic will be "Tax Treaty Primer - An Overview of Tax Treaties and Tax Treaty...
“Penny wise but pound foolish” first appeared in writing over 500 years ago. This idiom captures the wisdom of human experience in just five words: shortcuts that appear to save money are more expensive in the long run. Sometimes much more. Further proof of this eternal truth - and one taxpayer’s...
Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...